Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway

Fig. 3

Identification of DEGs in UCMSCs and UCMSCs/Mel. a RNA sequence (volcano maps overall distribution of the differential genes; KEGG analysis and GO analysis. b Transwell migration assay. c Giemsa staining. d Western blot analysis of AKT, PI3K, PDK1, PCNA, KI67, Cyclin E and Cyclin A expression levels in hUC-MSCs treated with melatonin and melatonin receptor inhibitor (luzindole). GAPDH was used as a loading control. e Quantitative analysis of the western blot results. UCMSC (hUC-MSCs); Mel (melatonin). Data are mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512